Promising combo study halted early: only 4 patients enrolled
Disease control
Terminated
This study tested whether adding the drug rapamycin to high-dose chemotherapy could help people with aggressive blood cancers that had come back or not responded to treatment. The trial was open to adults aged 18 to 65 with certain types of leukemia or lymphoma. Only 4 people too…
Phase: PHASE1, PHASE2 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated May 16, 2026 23:51 UTC